The CIS Insulin Market is expected to reach USD 3,008.5 million by 2020 growing at a CAGR of 15.0%, according to a new study by Grand View Research, Inc. The presence of an extensive pipeline portfolio of products exhibiting higher efficacies and their subsequent commercialization over the next six years is expected to serve this market as a high impact rendering driver. The introduction of government initiatives aimed at improving the affordability of insulin via price reduction, such as the collaboration between the government of Ukraine and Indar to reduce the price of insulin by 20% in 2013 is expected to have positive influence on demand. Some of the other drivers of this market include increasing attempts made by manufacturers to capitalize on the untapped opportunities by opening new manufacturing units to improve the supply of insulin and growing incidence rates of type II diabetes are some of the factors expected to fuel future market growth.
To request a sample copy or view summary of this report, click the link below:
Further key findings from the study suggest:
Regionally, Russia occupied the largest share of the market, accounting for 69.2% of the revenue. Its large share is majorly attributed by the subsidies that Russian government provides to make insulin more affordable for patients.
Ukraine is expected to register the fastest CAGR of 15.6% during the forecast period due to the presence of high untapped opportunities and encouraging government initiatives.
In addition, Poland is expected to grow at a lucrative rate during the forecast period majorly owing to the presence of high diabetes prevalence coupled with increasing healthcare expenditures.
Long acting insulin accounted for the largest share of the market, at over 39.0% in 2013, owing to the higher preference given to long acting insulin therapy for diabetes which results in lesser episodes of low blood sugar. It is also expected that this product segment will grow at the fastest CAGR of over 18.0% during the next six years.
Application of insulin for control of type II diabetes occupied for over 90.0% of the market owing to the presence of larger portfolio of products catering to this segment and a relatively larger prevalence base
Analogs accounted for over 80.0% of the revenue owing to their relatively higher prices and better efficacy levels. In addition, this segment is expected to exhibit the fastest CAGR during the forecast period on account of the introduction of technologically advanced products such as ultra-long and ultra-fast acting analogs.
Grand View Research has segmented the CIS Insulin market on the basis of product, application, source and region:
CIS Insulin Product Outlook
CIS Insulin Application Outlook
Type II Diabetes
Type I Diabetes
CIS Insulin Source Outlook
CIS Insulin Regional Outlook
Rest of CIS
Avail customized purchase options to meet your research needs:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."